DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Canada
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
CRON logo

Cronos Group Inc. Stock Price

TSX:CRON Community·CA$1.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CRON Share Price Performance

CA$4.68
1.23 (35.65%)
​
CA$4.68
Fair Value
CA$4.68
1.23 (35.65%)
Fairly Valued intrinsic discount
CA$4.68
Fair Value
Price CA$4.68
AnalystConsensusTarget CA$4.68
AnalystHighTarget CA$6.00
AnalystLowTarget CA$3.45
Sun, 14 Jun 26
Fair ValueCA$4.68
Share Pricen/a

CRON Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value CA$4.68 Fairly Valued intrinsic discount

GrowCo Capacity And Global Markets Will Unlock Potential

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value CA$6 22.0% undervalued intrinsic discount

Global Cannabis Legalization Will Expand Wellness And Medicine Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value CA$3.45 35.7% overvalued intrinsic discount

Regulatory Shifts In Israel And Germany Will Hinder Cannabis Growth

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
CRON logo
Cronos Group

Global Cannabis Legalization Will Expand Wellness And Medicine Markets

Cronos Group is betting that cannabis keeps moving from taboo to everyday use, and it’s building brands and overseas reach to be ready when rules loosen and demand rises. The catch is that shifting regulations, supply hiccups, and tougher competition could decide whether this turns into steady growth or a stalled story.Read more

View narrative
AN
AnalystHighTarget
CA$6
22.0% undervalued intrinsic discount
AnalystHighTarget's
Fair Value
Revenue
16.66% p.a.
Profit Margin
20.51%
Future PE
29.18x
Price in 2029
CA$7.24
View
CRON logo
Cronos Group

GrowCo Capacity And Global Markets Will Unlock Potential

Cronos Group is betting that new growing capacity and wider access to overseas medical markets can help it sell more cannabis products and rely less on any one country. The upside comes from its stronger brands and a shift toward products that typically earn more per sale, but delays, rule changes, and ongoing cash burn could quickly change the story.Read more

View narrative
AN
AnalystConsensusTarget
CA$4.68
Fairly Valued intrinsic discount
AnalystConsensusTarget's
Fair Value
Profit Margin
28.15%
Future PE
23.32x
Price in 2029
CA$5.62
View
CRON logo
Cronos Group

Regulatory Shifts In Israel And Germany Will Hinder Cannabis Growth

Cronos Group looks well set up to ride global demand for cannabis and wellness products, but its growth depends heavily on how rules and medical coverage change in places like Germany and Israel. See why some expect price pressure and rising compliance costs to make today’s progress harder to keep.Read more

View narrative
AN
AnalystLowTarget
CA$3.45
35.7% overvalued intrinsic discount
AnalystLowTarget's
Fair Value
Profit Margin
35.27%
Future PE
16.21x
Price in 2029
CA$4.15
View

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
CRON logo

CRON: Buybacks And Higher Multiple Will Support A Stronger Outlook

Fair Value: CA$6 22.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
CRON logo

CRON: Brand Strength And Rescheduling Tailwinds Will Support Future Upside

Fair Value: CA$4.68 Fairly Valued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
CRON logo

CRON: Partial Rescheduling Expectations Will Constrain Future Earnings Power

Fair Value: CA$3.45 35.7% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record.

1 Risk
3 Rewards
View Full Analysis

Cronos Group Inc. Key Details

US$179.1m

Revenue

US$102.1m

Cost of Revenue

US$77.0m

Gross Profit

US$7.1m

Other Expenses

US$70.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.19
43.02%
39.08%
0%
View Full Analysis

About CRON

Founded
n/a
Employees
610
CEO
Michael Gorenstein
WebsiteView website
thecronosgroup.com

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.

Recent CRON News & Updates

User avatar
Narrative Update • Aug 09

CRON: Buybacks And Higher Multiple Will Support A Stronger Outlook

Analysts have increased their Cronos Group price target by CA$1 to CA$6, reflecting updated assumptions regarding fair value, discount rate, growth, and margins following recent research updates. What’s in the News for Cronos Group Cronos Group announced a share repurchase program that allows the company to buy back up to 18,712,918 shares for $50 million.

Recent updates

No updates

Cronos Group Inc. Competitors

APTX logo

Apotex Health

Symbol: TSX:APTX
Market cap: CA$7.3b
CURA logo

Curaleaf Holdings

Symbol: TSX:CURA
Market cap: CA$3.5b
GTII logo

Green Thumb Industries

Symbol: CNSX:GTII
Market cap: CA$2.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide